Compound class:
Synthetic organic
Comment: This a tool compound reported as a prolylcarboxypeptidase (PRCP) inhibitor [1]. Additional structure-activity relationship (SAR) information for this (Example 12) and related compounds is provided in patent US8669252 B2 [2]. Prolylcarboxypeptidase is being investigated as a novel target for anti-obesity therapeutics due to its role in regulating metabolism.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Debenham JS, Graham TH, Verras A, Zhang Y, Clements MJ, Kuethe JT, Madsen-Duggan C, Liu W, Bhatt UR, Chen D et al.. (2013)
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett, 23 (23): 6228-33. [PMID:24157366] |
2. Shen DM, Debenham TH, Graham TH, Clements MJ, Zhang Y. (2014)
Prolylcarboxypeptidase inhibitors. Patent number: US8669252. Assignee: Merck Sharp & Dohme Corp.. Priority date: 17/05/2010. Publication date: 11/04/2014. |